Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Mark Aspinall-O'Dea

Showing results (1-10 of 12) with videos related to

Pageof 2
Sort By:
Proteomics. Clinical Applications|December 8, 2010
The pancreatic cancer proteome - recent advances and future promiseMark Aspinall-O'Dea, Eithne Costello
Pancreatology : Official Journal of the International Association of Pancreatology (IAP) ... [Et Al.]|August 7, 2009
Pancreatic cancer: proteomic approaches to a challenging diseaseSarah Tonack, Mark Aspinall-O'Dea, John P Neoptolemos, et al.
Proceedings of the National Academy of Sciences of the United States of America|December 4, 2002
In vitro reconstitution of the activated zeaxanthin state associated with energy dissipation in plantsMark Aspinall-O'Dea, Mark Wentworth, Andy Pascal, et al.
Plos One|June 30, 2012
Identification of nuclear protein targets for six leukemogenic tyrosine kinases governed by post-translational regulationAndrew Pierce, Andrew Williamson, Ewa Jaworska, et al.
European Journal of Haematology|March 13, 2014
Monocyte-derived dendritic cells from chronic myeloid leukaemia have abnormal maturation and cytoskeletal function that is associated with defective localisation and signalling by normal ABL1 proteinSarah Brown, Claire V Hutchinson, Mark Aspinall-O'Dea, et al.
Nature Protocols|December 19, 2014
Antibody-based detection of protein phosphorylation status to track the efficacy of novel therapies using nanogram protein quantities from stem cells and cell linesMark Aspinall-O'Dea, Andrew Pierce, Francesca Pellicano, et al.
Journal of Proteomics|August 5, 2009
A technically detailed and pragmatic protocol for quantitative serum proteomics using iTRAQSarah Tonack, Mark Aspinall-O'Dea, Rosalind E Jenkins, et al.
BMJ Open Respiratory Research|February 27, 2016
ERK and AKT phosphorylation status in lung cancer and emphysema using nanocapillary isoelectric focusingPhilip A J Crosbie, Emma J Crosbie, Mark Aspinall-O'Dea, et al.
Toxicologic Pathology|January 28, 2025
Applications of Cell-Based Protein Array Technology to Preclinical Safety Assessment of Biological ProductsAxel Vicart, Cam Holland, Kathryn Fraser, et al.
Stem Cells (Dayton, Ohio)|May 9, 2014
The antiproliferative activity of kinase inhibitors in chronic myeloid leukemia cells is mediated by FOXO transcription factorsFrancesca Pellicano, Mary T Scott, G Vignir Helgason, et al.
Pageof 2

Showing results (1-10 of 12) with videos related to

Sort By:
Pageof 2
Proteomics. Clinical Applications|December 8, 2010
The pancreatic cancer proteome - recent advances and future promiseMark Aspinall-O'Dea, Eithne Costello
Pancreatology : Official Journal of the International Association of Pancreatology (IAP) ... [Et Al.]|August 7, 2009
Pancreatic cancer: proteomic approaches to a challenging diseaseSarah Tonack, Mark Aspinall-O'Dea, John P Neoptolemos, et al.
Proceedings of the National Academy of Sciences of the United States of America|December 4, 2002
In vitro reconstitution of the activated zeaxanthin state associated with energy dissipation in plantsMark Aspinall-O'Dea, Mark Wentworth, Andy Pascal, et al.
Plos One|June 30, 2012
Identification of nuclear protein targets for six leukemogenic tyrosine kinases governed by post-translational regulationAndrew Pierce, Andrew Williamson, Ewa Jaworska, et al.
European Journal of Haematology|March 13, 2014
Monocyte-derived dendritic cells from chronic myeloid leukaemia have abnormal maturation and cytoskeletal function that is associated with defective localisation and signalling by normal ABL1 proteinSarah Brown, Claire V Hutchinson, Mark Aspinall-O'Dea, et al.
Nature Protocols|December 19, 2014
Antibody-based detection of protein phosphorylation status to track the efficacy of novel therapies using nanogram protein quantities from stem cells and cell linesMark Aspinall-O'Dea, Andrew Pierce, Francesca Pellicano, et al.
Journal of Proteomics|August 5, 2009
A technically detailed and pragmatic protocol for quantitative serum proteomics using iTRAQSarah Tonack, Mark Aspinall-O'Dea, Rosalind E Jenkins, et al.
BMJ Open Respiratory Research|February 27, 2016
ERK and AKT phosphorylation status in lung cancer and emphysema using nanocapillary isoelectric focusingPhilip A J Crosbie, Emma J Crosbie, Mark Aspinall-O'Dea, et al.
Toxicologic Pathology|January 28, 2025
Applications of Cell-Based Protein Array Technology to Preclinical Safety Assessment of Biological ProductsAxel Vicart, Cam Holland, Kathryn Fraser, et al.
Stem Cells (Dayton, Ohio)|May 9, 2014
The antiproliferative activity of kinase inhibitors in chronic myeloid leukemia cells is mediated by FOXO transcription factorsFrancesca Pellicano, Mary T Scott, G Vignir Helgason, et al.
Pageof 2